Lobectomy offers improved survival outcomes relative to segmentectomy for >2 but ≤4 cm non–small cell lung cancer tumors

• DOI: 10.1016/j.xjon.2022.03.002
• Publication Date: 2022-04-14T06:09:53Z
• Authors: Terrance Peng; Sean C. Wightman; Li Ding; Dustin K. Lieu; Scott M. Atay; Elizabeth A. David; Anthony W. Kim
• Keywords: Adjuvant Therapy

The objective was to compare overall survival (OS) between lobectomy and segmentectomy for patients with non-small cell lung cancers (NSCLCs) > 2 but ≤4 cm.The National Cancer Database queried identify treatment-naïve NSCLC tumors >2 cm. Eligible were diagnosed pT1 or T2 N0 M0 disease, underwent segmentectomy, received no adjuvant therapy. OS compared using the Kaplan-Meier method, Cox proportional-hazards model used prognostic factors death. Propensity score matching performed minimize effects of potential confounders.Included 32,792 patients: (n = 31,353) 1439). Five-year improved following over cm NSCLCs (62.3% vs 52.6%; P < .0001). Further stratification demonstrated 5-year segmentectomy: ≤3 (64.9% 54.3%; .0001) >3 (56.9% 47.6%; .0003). In a Charlson-Deyo comorbidity index 0, greater (67.1% 62.1%; .03). 0 3 (61.8% 54.6%; .02). Segmentectomy increased risk death in year 1 through 5 postoperative period (hazard ratio, 1.35; remained after propensity (59.6% 52.7%; .02).Lobectomy is associated superior may be preferred when feasible.